GILD

SEC source: 0001127602-24-014767 · form4.xml · derivative · entry 2

Horning Sandra · CIK 0001638709 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,648

Underlying: Common Stock · 12,648 shares

Expires 2034-05-08

F3 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 8, 2024.

SEC source: 0001127602-24-014767 · form4.xml · derivative · entry 1

Horning Sandra · CIK 0001638709 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,801

Underlying: Common Stock · 2,310 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: 100% of the restricted stock units vested immediately upon the grant date of May 8, 2024.

F2 · derivative.expiration_date: 100% of the restricted stock units vested immediately upon the grant date of May 8, 2024.

SEC source: 0001127602-24-014809 · form4.xml · derivative · entry 2

Bluestone Jeffrey · CIK 0001771814 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,648

Underlying: Common Stock · 12,648 shares

Expires 2034-05-08

F3 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 8, 2024.

SEC source: 0001127602-24-014809 · form4.xml · derivative · entry 1

Bluestone Jeffrey · CIK 0001771814 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,197

Underlying: Common Stock · 2,310 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: 100% of the restricted stock units vested immediately upon the grant date of May 8, 2024.

F2 · derivative.expiration_date: 100% of the restricted stock units vested immediately upon the grant date of May 8, 2024.

SEC source: 0001127602-24-014812 · form4.xml · derivative · entry 3

MANWANI HARISH · CIK 0001527726 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,648

Underlying: Common Stock · 12,648 shares

Expires 2034-05-08

F2 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 8, 2024.

SEC source: 0001127602-24-014812 · form4.xml · nonDerivative · entry 2

MANWANI HARISH · CIK 0001527726 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,873

SEC source: 0001127602-24-014812 · form4.xml · nonDerivative · entry 1

MANWANI HARISH · CIK 0001527726 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,324

F1 · security: Represents 2,310 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of May 8, 2024.

SEC source: 0001127602-24-014814 · form4.xml · derivative · entry 2

WELTERS ANTHONY · CIK 0001213307 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,648

Underlying: Common Stock · 12,648 shares

Expires 2034-05-08

F2 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 8, 2024.

SEC source: 0001127602-24-014814 · form4.xml · nonDerivative · entry 1

WELTERS ANTHONY · CIK 0001213307 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,232

F1 · security: Represents 2,310 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of May 8, 2024.

SEC source: 0001127602-24-014816 · form4.xml · derivative · entry 2

Rodriguez Javier · CIK 0001415548 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,648

Underlying: Common Stock · 12,648 shares

Expires 2034-05-08

F2 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 8, 2024.

SEC source: 0001127602-24-014816 · form4.xml · nonDerivative · entry 1

Rodriguez Javier · CIK 0001415548 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,702

F1 · security: Represents 2,310 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of May 8, 2024.

SEC source: 0001127602-24-014834 · form4.xml · derivative · entry 2

BARTON JACQUELINE K · CIK 0001183680 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,648

Underlying: Common Stock · 12,648 shares

Expires 2034-05-08

F2 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 8, 2024.

SEC source: 0001127602-24-014834 · form4.xml · nonDerivative · entry 1

BARTON JACQUELINE K · CIK 0001183680 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,540

F1 · security: Represents 2,310 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of May 8, 2024.

SEC source: 0001127602-24-014818 · form4.xml · derivative · entry 2

LOVE TED W · CIK 0001188919 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,648

Underlying: Common Stock · 12,648 shares

Expires 2034-05-08

F2 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 8, 2024.

SEC source: 0001127602-24-014818 · form4.xml · nonDerivative · entry 1

LOVE TED W · CIK 0001188919 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,822

F1 · security: Represents 2,310 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of May 8, 2024.

SEC source: 0001127602-24-013462 · form4.xml · derivative · entry 3

Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,568

Underlying: Common Stock · 515 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-24-013462 · form4.xml · nonDerivative · entry 2

Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,114

SEC source: 0001127602-24-013462 · form4.xml · nonDerivative · entry 1

Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,272

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-24-011987 · form4.xml · nonDerivative · entry 1

Parsey Merdad · CIK 0001792150 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 96,304

F1 · kind: The sale transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on November 9, 2023.

SEC source: 0001127602-24-011458 · form4.xml · derivative · entry 1

Lofton Kevin E · CIK 0001468818 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,258.1388

Underlying: Common Stock · 33.8931 shares

Expires not disclosed

F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock.

F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate.

F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person.

F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person.

SEC source: 0001127602-24-009540 · form4.xml · derivative · entry 7

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,407

Underlying: Common Stock · 17,305 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F4 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F4 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-24-009540 · form4.xml · derivative · entry 6

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,970

Underlying: Common Stock · 87,970 shares

Expires 2034-03-10

F5 · derivative.exercise_date: The options have a four year vesting schedule. 25% vest on the first anniversary date of the date grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-24-009540 · form4.xml · derivative · entry 5

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,333

Underlying: Common Stock · 6,707 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F4 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F4 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-24-009540 · form4.xml · derivative · entry 4

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,040

Underlying: Common Stock · 3,025 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F3 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.

F3 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.

SEC source: 0001127602-24-009540 · form4.xml · nonDerivative · entry 3

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 134,983

SEC source: 0001127602-24-009540 · form4.xml · nonDerivative · entry 2

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 139,488

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-24-009540 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 132,781

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · balance_after: Balance adjusted to reflect shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan.

SEC source: 0001127602-24-009542 · form4.xml · derivative · entry 7

Mercier Johanna · CIK 0001782135 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,448

Underlying: Common Stock · 17,305 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-24-009542 · form4.xml · derivative · entry 6

Mercier Johanna · CIK 0001782135 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,970

Underlying: Common Stock · 87,970 shares

Expires 2034-03-10

F4 · derivative.exercise_date: The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-24-009542 · form4.xml · derivative · entry 5

Mercier Johanna · CIK 0001782135 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,143

Underlying: Common Stock · 6,819 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-24-009542 · form4.xml · derivative · entry 4

Mercier Johanna · CIK 0001782135 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,962

Underlying: Common Stock · 3,025 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested.

SEC source: 0001127602-24-009542 · form4.xml · nonDerivative · entry 3

Mercier Johanna · CIK 0001782135 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 118,432

SEC source: 0001127602-24-009542 · form4.xml · nonDerivative · entry 2

Mercier Johanna · CIK 0001782135 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 122,991

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-24-009542 · form4.xml · nonDerivative · entry 1

Mercier Johanna · CIK 0001782135 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 116,172

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-24-009544 · form4.xml · derivative · entry 7

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 135,862

Underlying: Common Stock · 54,910 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-24-009544 · form4.xml · derivative · entry 6

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 279,130

Underlying: Common Stock · 279,130 shares

Expires 2034-03-10

F4 · derivative.exercise_date: The options have a four-year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-24-009544 · form4.xml · derivative · entry 5

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,952

Underlying: Common Stock · 19,140 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-24-009544 · form4.xml · derivative · entry 4

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,092

Underlying: Common Stock · 10,800 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested.

SEC source: 0001127602-24-009544 · form4.xml · nonDerivative · entry 3

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 484,847

SEC source: 0001127602-24-009544 · form4.xml · nonDerivative · entry 2

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 498,629

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-24-009544 · form4.xml · nonDerivative · entry 1

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 479,489

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-24-009546 · form4.xml · derivative · entry 7

Parsey Merdad · CIK 0001792150 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,214

Underlying: Common Stock · 17,640 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-24-009546 · form4.xml · derivative · entry 6

Parsey Merdad · CIK 0001792150 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 89,660

Underlying: Common Stock · 89,660 shares

Expires 2034-03-10

F4 · derivative.exercise_date: The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-24-009546 · form4.xml · derivative · entry 5

Parsey Merdad · CIK 0001792150 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,574

Underlying: Common Stock · 6,946 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-24-009546 · form4.xml · derivative · entry 4

Parsey Merdad · CIK 0001792150 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,520

Underlying: Common Stock · 3,455 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested.

SEC source: 0001127602-24-009546 · form4.xml · nonDerivative · entry 3

Parsey Merdad · CIK 0001792150 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 98,304

SEC source: 0001127602-24-009546 · form4.xml · nonDerivative · entry 2

Parsey Merdad · CIK 0001792150 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 103,107

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-24-009546 · form4.xml · nonDerivative · entry 1

Parsey Merdad · CIK 0001792150 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,161

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-24-009708 · form4.xml · derivative · entry 7

Patterson Sandra · CIK 0001968906 · SVP, Controllership

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,663

Underlying: Common Stock · 4,825 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F4 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F4 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-24-009708 · form4.xml · derivative · entry 6

Patterson Sandra · CIK 0001968906 · SVP, Controllership

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,660

Underlying: Common Stock · 13,660 shares

Expires 2034-03-10

F5 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested.